Executives Increasing Stock Purchases.. U.S. Bio Firms Targeting Rare Diseases Observed

Prothena Corporation (NASDAQ: PRTA) reported first-quarter net income of approximately $32.7 million, driven by the receipt of a $50 million (approximately KRW 70 billion) milestone payment from Novo Nordisk, and significantly lowered its full-year cash-burn guidance. The company has launched a share-repurchase program of up to $100 million (approximately KRW 140 billion), during which insiders—including William P. Scully—added roughly $1.5 million (approximately KRW 2 billion) worth of shares through open-market purchases. As of quarter-end, Prothena held $330.3 million (approximately KRW 460 billion) in cash and restricted cash, remained debt-free, and noted the potential for an additional $55 million in milestone payments. At its recent annual meeting, shareholders approved all key items—including director reappointments, selection of an external auditor, and executive compensation policies—thereby reaffirming the existing board and governance structure. Some institutional investors are also “buying the dip”; notably, Canadian asset manager Connor, Clark & Lunn Investment Management increased its stake by more than 24% as of quarter-end. Prothena is a late-stage clinical biotech company targeting protein misfolding to develop therapies for severe neurodegenerative and rare diseases—such as Parkinson’s disease, Alzheimer’s disease, and ATTR amyloidosis—and has previously divested certain assets to Novo Nordisk. Through partnerships with major pharmaceutical firms including Novo Nordisk, Roche, and Bristol Myers Squibb, the company co-develops its pipeline and anticipates further milestone payments and future royalty revenues as its clinical programs advance.